医药行业分析
- (2025-01-13)
- (2025-01-13)
- (2025-01-12)
- (2025-01-12)
- (2025-01-12)
- (2025-01-11)
- (2025-01-11)
- (2025-01-10)
- (2025-01-10)
- (2025-01-10)
- (2025-01-10)
- (2025-01-10)
- (2025-01-10)
- (2025-01-10)
- (2025-01-10)
- (2025-01-10)
- (2025-01-10)
- (2025-01-10)
- (2025-01-10)
- (2025-01-10)
- (2025-01-10)
- (2025-01-10)
ORR 87.5%,迈威生物靶向 Nectin-4 ADC 创新药 9MW2821联合治疗一线被纳入 CDE 突破性治疗品种名单
(2025-01-10)- (2025-01-09)
- (2025-01-09)
- (2025-01-09)
- (2025-01-09)
- (2025-01-09)
- (2025-01-09)
- (2025-01-09)
- (2025-01-09)
- (2025-01-09)
ORR 87.5%,迈威生物靶向 Nectin-4 ADC 创新药 9MW2821联合治疗一线被纳入 CDE 突破性治疗品种名单
(2025-01-09)- (2025-01-09)
- (2025-01-09)
- (2025-01-09)
- (2025-01-09)
- (2025-01-08)
- (2025-01-08)
- (2025-01-08)
- (2025-01-08)
- (2025-01-08)
- (2025-01-08)
- (2025-01-08)
- (2025-01-08)
- (2025-01-07)
- (2025-01-07)
- (2025-01-07)
- (2025-01-07)
- (2025-01-07)
- (2025-01-07)
- (2025-01-07)
- (2025-01-07)
- (2025-01-07)
- (2025-01-07)
- (2025-01-07)
- (2025-01-06)
- (2025-01-06)
- (2025-01-06)
- (2025-01-06)